MyImmune Secures Pre-Seed Investment to Accelerate Development of AI-Powered Diagnostic and Therapeutic Platform

October 23, 2024 - Delaware, USA - MyImmune, a cutting-edge biotech company leveraging AI to revolutionize disease diagnosis, has secured a pre-seed investment led by Osaka University Venture Capital Co., Ltd. (OUVC). This funding will be used to accelerate the development of MyImmune's AI-powered platform, which not only enables early and accurate disease diagnosis but also advances therapeutic development through analysis of the immune system.

Founded by a multidisciplinary team including Prof. Daron Standley, PhD, Dr. Florian Hauer, and AI expert Ayan Sengupta, MyImmune's innovative platform analyzes the body's immune response using patented AI algorithms. By harnessing the power of immune cells, MyImmune can detect elusive and underserved diseases such as cancer, autoimmune disorders, and infectious diseases from a small blood sample. This platform also has significant implications for therapeutic discovery, providing insights into antibody development, vaccine target identification, and personalized immunotherapies.

"The investment from OUVC is a significant milestone for us as we expand the capabilities of our platform to not only detect diseases early but also contribute to the development of new treatments," said Dr. Florian Hauer, CEO of MyImmune. "Our technology has the potential to revolutionize healthcare by integrating diagnostics and therapeutics into one cohesive platform powered by AI."

The support from OUVC No. 2 Fund, a prominent investor in ventures from Osaka University, demonstrates strong confidence in MyImmune's dual-purpose platform. With the ability to provide deeper insights into immune responses, MyImmune aims to collaborate with hospitals, biotech companies, and pharmaceutical firms to drive both diagnostic advancements and therapeutic innovations.

251 Little Falls Drive
Wilmington, DE 19808
USA
Press contact: Florian Hauer, PhD via press@myimmune.ai

About MyImmune
Founded in 2024, MyImmune is advancing an AI-powered biotech platform transforming the landscape of diagnostics and therapeutic development. By leveraging immune cell data, MyImmune enables early disease detection and facilitates the discovery of new treatments. The company is based in Delaware, USA.

About OUVC No. 2 Fund
OUVC No. 2 Fund supports ventures emerging from Osaka University research, with a focus on innovative technologies. The fund has a total size of 10.65 billion yen and invests in ventures across healthcare and other high-impact sectors.

For more information, visit https://myimmune.ai.

This release was published on openPR.